Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | $260.50K | $123.44K | $3.10M | $698.47K | $1.12M | $4.04M | $2.06M |
| Cost of Revenue | $26.27K | $13.62M | $6.72K | $11.36M | $893.80K | $2.55M | $3.65M | $1.76M |
| Gross Profit | $-26.27K | $-13.36M | $116.72K | $-8.26M | $-195.33K | $-1.43M | $393.85K | $305.25K |
| Gross Margin | 0.00% | -5127.77% | 94.55% | -266.35% | -27.97% | -127.36% | 9.75% | 14.81% |
| Operating Expenses | $28.56M | $6.73M | $18.25M | $6.51M | $2.62M | $4.27M | $2.52M | $710.38K |
| Operating Income | $-28.59M | $-20.09M | $-18.13M | $-14.77M | $-2.82M | $-5.70M | $-2.12M | $-405.13K |
| Operating Margin | 0.00% | -7712.01% | -14686.17% | -476.23% | -403.52% | -507.52% | -52.52% | -19.66% |
| Net Income | $-27.52M | $-19.03M | $-18.05M | $-14.79M | $-2.85M | $-5.72M | $-2.15M | $-436.07K |
| Net Margin | 0.00% | -7304.75% | -14625.85% | -476.88% | -407.73% | -509.73% | -53.27% | -21.16% |
| EPS (Basic) | $-1.16 | $-3.57 | $-4.26 | $-4.88 | $-1.72 | $-3.34 | $-1.61 | $-0.25 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |